Coronavirus Vaccine in India Drug Controller of India Hold Meeting to Sii Application for Emergency Use Approval – Vaccine in India: Kovishield can be approved today, meeting of expert committee continues

Corona virus cases are increasing in the country. The Corona vaccine is expected to arrive on the new year. In the same sequence, on Wednesday, an expert panel of Drugs Controller of India (DCI) is meeting to give emergency approval to Vaccine Kovshield of Serum Institute of India (SII), one of the vaccine manufacturers in India. When the vaccine was approved in the UK, SII executive officer Adar Poonawala said this was good news.

This decision has been taken at a time when Britain’s Boris Johnson government has allowed the use of the Corona Vaccine Covishield in the country for emergency use. This vaccine has been developed by Oxford University and AstraZeneca together. In India, Pune’s Serum Institute of India is manufacturing this vaccine.

ALSO READ- Corona: Oxford Vaccine Approved In Britain, Possibility Of Approval Soon In India

A government official says that the Subject Expert Committee (SEC) of the Drugs Controller of India (DCI) is holding a meeting to consider Serum Institute of India’s application for emergency use approval of the Kovid-19 vaccine.

The Central Drugs Standard Control Organization (CDSCO) sought safety and immunogenicity data of clinical evaluation abroad before SII was approved for emergency use in India. The SEC recommended that the company should submit an updated safety data of Phase II and Phase III clinical trials in the UK and India.

Kovishield hopes to get emergency permission in India
Vaccine approval in the UK is a major achievement for the Serum Institute, as it is one of the top three vaccine manufacturers in India. The serum has already applied to the Drug Controller General of India for regulatory approval, but has not yet received mandatory approval for the vaccine. There is a possibility that it may be approved in today’s meeting.

Corona virus cases are increasing in the country. The Corona vaccine is expected to arrive on the new year. In the same sequence, on Wednesday, an expert panel of Drugs Controller of India (DCI) is meeting to give emergency approval to Vaccine Kovshield of Serum Institute of India (SII), one of the vaccine manufacturers in India. When the vaccine was approved in the UK, SII executive officer Adar Poonawala said this was good news.

This decision has been taken at a time when Britain’s Boris Johnson government has allowed the use of the Corona Vaccine Covishield in the country for emergency use. This vaccine has been developed by Oxford University and AstraZeneca together. In India, Pune’s Serum Institute of India is manufacturing this vaccine.

ALSO READ- Corona: Oxford Vaccine Approved In Britain, Possibility Of Approval Soon In India

A government official says that the Subject Expert Committee (SEC) of the Drugs Controller of India (DCI) is holding a meeting to consider Serum Institute of India’s application for emergency use approval of the Kovid-19 vaccine.

Subject Expert Committee (SEC) of Drugs Controller of India to take a meeting to consider Serum Institute of India’s application for emergency use approval of its COVID19 vaccine, says a government official

– ANI (@ANI) December 30, 2020

The Central Drugs Standard Control Organization (CDSCO) sought safety and immunogenicity data of clinical evaluation abroad before SII was approved for emergency use in India. The SEC recommended that the company should submit an updated safety data of Phase II and Phase III clinical trials in the UK and India.

Kovishield hopes to get emergency permission in India
Vaccine approval in the UK is a major achievement for the Serum Institute, as it is one of the top three vaccine manufacturers in India. The serum has already applied to the Drug Controller General of India for regulatory approval, but has not yet received mandatory approval for the vaccine. There is a possibility that it may be approved in today’s meeting.